Amneal Pharmaceuticals, Inc. (AMRX)
20.30
+0.23
(+1.15%)
USD |
NASDAQ |
Oct 02, 16:00
20.44
+0.14
(+0.69%)
After-Hours: 20:00
Amneal Pharmaceuticals Enterprise Value : 9.222B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 9.222B |
| October 01, 2026 | 9.148B |
| September 30, 2026 | 9.171B |
| September 29, 2026 | 9.190B |
| September 28, 2026 | 9.286B |
| September 25, 2026 | 9.053B |
| September 24, 2026 | 9.064B |
| September 23, 2026 | 8.912B |
| September 22, 2026 | 8.966B |
| September 21, 2026 | 9.177B |
| September 18, 2026 | 8.714B |
| September 17, 2026 | 8.577B |
| September 16, 2026 | 8.513B |
| September 15, 2026 | 8.056B |
| September 14, 2026 | 8.238B |
| September 11, 2026 | 8.171B |
| September 10, 2026 | 8.127B |
| September 09, 2026 | 8.248B |
| September 08, 2026 | 8.184B |
| September 04, 2026 | 8.309B |
| September 03, 2026 | 8.446B |
| September 02, 2026 | 8.507B |
| September 01, 2026 | 8.385B |
| August 31, 2026 | 8.318B |
| August 28, 2026 | 8.340B |
| Date | Value |
|---|---|
| August 27, 2026 | 8.491B |
| August 26, 2026 | 8.484B |
| August 25, 2026 | 8.462B |
| August 24, 2026 | 8.417B |
| August 21, 2026 | 8.459B |
| August 20, 2026 | 8.455B |
| August 19, 2026 | 8.523B |
| August 18, 2026 | 8.548B |
| August 17, 2026 | 8.621B |
| August 14, 2026 | 8.535B |
| August 13, 2026 | 8.254B |
| August 12, 2026 | 8.379B |
| August 11, 2026 | 8.200B |
| August 10, 2026 | 8.449B |
| August 07, 2026 | 8.532B |
| August 06, 2026 | 8.510B |
| August 05, 2026 | 8.634B |
| August 04, 2026 | 8.641B |
| August 03, 2026 | 8.759B |
| July 31, 2026 | 8.590B |
| July 30, 2026 | 8.647B |
| July 29, 2026 | 8.839B |
| July 28, 2026 | 8.730B |
| July 27, 2026 | 8.516B |
| July 24, 2026 | 8.462B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 2.451B |
| Eli Lilly & Co. | 1.122T |
| Johnson & Johnson | 644.86B |
| Merck & Co., Inc. | 403.00B |
| Viatris, Inc. | 32.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 69.61M |
| Revenue (Quarterly) | 796.20M |
| Total Expenses (Quarterly) | 738.54M |
| EPS Diluted (Quarterly) | 0.1757 |
| Gross Profit Margin (Quarterly) | 42.01% |
| Profit Margin (Quarterly) | 8.74% |
| Earnings Yield | 2.36% |
| Operating Earnings Yield | 7.17% |
| Normalized Earnings Yield | 3.061 |